Top Areas of Focus

Cardiovascular metabolic system diseases

Cardiovascular metabolic disease is a kind of diseases that seriously endangers human health, mainly including hypertension, hyperlipidemia, diabetes, coronary atherosclerotic heart disease, obesity, and non-alcoholic fatty liver disease, which is drawing increasing awareness. Many of these diseases occur together, share common risk factors, and are associated with increased risks of disability, cancer, and premature deaths.

 

Central nervous system diseases

Central nervous system diseases represent a spectrum of diseases ranging from mild neurological impairment that may have motor, sensory, visual, speech, cognitive manifestations, or a combination thereof, to comatose states and brain death. At present, nearly one in six people worldwide suffer from disorders of the CNS.

 

Skin diseases

Hair loss is a type of skin disease, and the common types of hair loss are mainly divided into androgenic alopecia, alopecia areata, psychogenic alopecia, genetic alopecia, etc. 95% of the hair loss belongs to androgenic alopecia.

 

As a biotech solutions ltd, we can provide professional innovative therapeutic solutions, life therapeutic solutions for clients, anything you need, please contact us.

 

We have been engaged in the biopharma industries for many years. We have amassed extensive experience and profound knowledge in the field of central nervous system diseases. Our team of experts is dedicated to developing cutting-edge therapeutic approaches to address a variety of neurological disorders. We employ advanced technologies and innovative research methods to strive for breakthroughs in the treatment of central nervous system diseases, aiming to bring hope and an improved quality of life to patients suffering from these conditions.

 

Enjoyed this article? Stay informed by joining our newsletter!

Comments

You must be logged in to post a comment.

About Author

Youngen, based in Beijing, is a biotechnology company pioneering the development of next-generation siRNA drugs to silence specific mRNAs and reduce the production of proteins that cause disease. Youngen has been dedicating to bring RNAi therapeutics to a broad spectrum of difficult-to-treat diseases, both rare and general population impacting millions of people around the world. Leveraging these platform technologies, we built diversified product pipelines with globally competitive, first-in-class and best-in-class potential. We’re exploring many therapeutic areas to bring more treatment options to the patients with metabolic and cardiovascular diseases, immune-mediated diseases, and neurological disorders. https://www.youngenbiomed.com/